Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Nodules and Chilblains in a Toddler
Description
The case discussed involves a toddler female patient who developed chilblains and nodular lesions from two months of age, alongside a history of altered muscle tone and developmental regression by 14 months. The patient exhibited symptoms indicative of an interferonopathy, which is a rare type of auto-inflammatory disorder characterized by systemic inflammation and could involve multiple organ dysfunctions. Despite extensive testing, all antibody tests and myositis tests returned normal results, raising suspicions for an auto-inflammatory condition. The discussion highlighted the mechanics of type 1 interferonopathies, detailing how genetic mutations affecting nucleic acid metabolism may cause chronic inflammation resembling a viral infection response. Genetic testing, including whole exome and genome sequencing, revealed a variant of unknown significance, leading to the final diagnosis of an unclassifiable type 1 interferonopathy. Treatment options discussed included genetic and biomarker approaches, with recommendations for corticosteroids and novel therapies targeting the interferon pathway, such as Jack inhibitors. The complexities involved in diagnosing and managing interferonopathies emphasize the necessity for advanced genetic and cytokine analysis in similar pediatric cases.
View moreConclusions
- The toddler presented with chilblain-like lesions and symptoms indicative of an auto-inflammatory disorder, likely an interferonopathy.
- Despite extensive testing, including antibody tests, the patient's immune system appeared normal with no significant findings.
- Genetic testing did not reveal known mutations associated with recognized interferonopathies but indicated a variant of unknown significance in TAF1.
- A strong type 1 interferon gene signature was detected, supporting the diagnosis of an interferonopathy.
- Treatment options discussed included corticosteroids and JAK inhibitors, which have shown promise in managing interferonopathies.
- The case highlights the importance of recognizing early signs of interferonopathies in children, especially with a multi-organ inflammatory presentation.
- Further research is warranted to explore the implications of the TAF1 variant in the context of interferonopathies.
- Wang CS. Type I Interferonopathies: A Clinical Review. Rheum Dis Clin North Am. 2023;49(4):741-756.
- Adang LA, D'Aiello R, Takanohashi A, et al. IFN-signaling gene expression as a diagnostic biomarker for monogenic interferonopathies. JCI Insight. 2024;9(14):e178456. doi:10.1172/jci.insight.178456.
- Kolivras A, Aeby A, Crow YJ, Rice GI, Sass U, André J. Cutaneous histopathological findings of Aicardi-Goutières syndrome, overlap with chilblain lupus. J Cutan Pathol. 2008;35(8):774-778. doi:10.1111/j.1600-0560.2007.00900.x
- Weidler S, Koss S, Wolf C, Lucas N, Brunner J, Lee-Kirsch MA. A rare manifestation of STING-associated vasculopathy with onset in infancy: a case report. Pediatr Rheumatol Online J. 2024;22(1):9. doi:10.1186/s12969-023-00934-4.
- Zhang S, Liu X, Chen W, Zhang K, Wu Q, Wei Y. Targeting TAF1 with BAY-299 induces antitumor immunity in triple-negative breast cancer. Biochem Biophys Res Commun. 2023;665:55-63. doi:10.1016/j.bbrc.2023.04.100.
- Rice GI, Meyzer C, Bouazza N, et al. Reverse-Transcriptase Inhibitors in the Aicardi-Goutières Syndrome. N Engl J Med. 2018;379(23):2275-2277. doi:10.1056/NEJMc1810983.
- Liu Y, et al. Activated STING in a Vascular and Pulmonary Syndrome. N Engl J Med. 2014;371(6):507-518. doi:10.1056/NEJMoa1403148.